Meteor Biotech has joined a South Korean government-backed consortium aimed at developing scalable technologies for the commercialisation of brain organoids over a seven-year programme supported by the Ministry of Science and ICT.

Meteor Biotech has joined a seven-member consortium in South Korea focused on overcoming key barriers to the commercialisation of brain organoids, including manufacturing standardisation, scalability, quality control and analytical validation.

The initiative, titled Development of Core Technology for the Commercialisation of Brain Organoids, is a KRW 14.2 billion (approximately $10 million) programme led by Sungkyunkwan University and supported by the South Korean Ministry of Science and ICT.

The consortium includes academic, research and industry partners such as the Korea Brain Research Institute and the Korea Institute of Toxicology, alongside biotechnology companies working on organoids, regenerative medicine and drug screening technologies.

Brain organoids are stem cell-derived three-dimensional models of human brain tissue that are increasingly used in neuroscience research, drug discovery and toxicity testing. They are also being explored as potential alternatives to animal models in preclinical research.

However, the field continues to face challenges around reproducibility, scalability and the preservation of biologically relevant spatial information during analysis.

As part of the programme, Meteor Biotech will contribute its SLACS (Spatially-resolved Laser Activated Cell Sorting) technology, which is designed to isolate spatially defined cell populations from tissue sections while retaining structural context for downstream molecular analysis.

Dr Amos Lee, chief executive officer at Meteor Biotech, said spatial organisation is a key determinant of disease relevance in organoid systems.

“Brain organoids are powerful because their biology is inherently spatial,” Lee said. “The disease relevance of an organoid depends not only on which cells are present, but also on where they are located and how they interact within a three-dimensional structure. The next challenge for the field is to move beyond simply observing spatial patterns and to begin selecting the cells and microenvironments that truly drive disease biology.”

The SLACS platform is intended to support analysis of complex organoid systems by enabling researchers to recover individual cells or defined spatial regions for molecular profiling, potentially improving understanding of disease mechanisms and therapeutic response.

The seven-year programme is intended to establish an integrated platform for brain organoid development and standardisation, supporting applications in disease modelling, precision medicine and drug discovery.